Table I.

Patient characteristics and FDG PET-CT observations.

					FDG PET-CT observation
Patient no.	Age, years	Gleason score	Therapeutic history	PSA on imaging, ng/ml	Prostatic fossa	Lymph nodes	Bone (or other)	Confirmatory test
1	59	7	Initial staging	6.8	−	+	+	BS and CT
2	61	9	Initial staging	14	−	+	−	CT and PLND
3	52	6	Initial staging	49	+	−	−	CT and BS
4	50	7	Initial staging	6.1	−	−	−	CT and BS
5	73	8	Initial staging	680	+	+	+	CT and BS
6	69	6	Initial staging	9.6	−	−	−	CT
7	53	8	Initial staging	511	−	+	+	BS and CT
8	59	7	Initial staging	369	−	−	+	BS and CT
9	71	9	Initial staging	980	+	+	+	BS and CT
10	64	6	Prostatectomy	3.1	−	−	+	BS and CT
11	63	6	Prostatectomy	22.5	−	+	−	CT
12	55	8	Prostatectomy	10.7	−	+	−	CT
13	70	7	Prostatectomy	67	−	−	+	BS and CT
14	72	6	Prostatectomy	15.4	−	−	+ (lung)	Lung Bx
15	64	6	Prostatectomy	3.8	−	−	−	CT and repeat PET
16	68	7	Prostatectomy	14	−	−	+	Bx
17	72	7	Prostatectomy	8.4	−	−	+	CT
18	67	8	Hormone	11.5	−	−	+	BS and CT
19	60	9	Brachytherapy	15.7	−	−	+	BS and CT
20	70	8	Brachytherapy	5.5	−	−	−	CT
21	72	7	Brachytherapy	7.8	+	−	−	Bx
22	77	7	Brachytherapy	4.8	−	−	−	None
23	64	7	Hormone + XRT	41	−	+	−	CT
24	62	7	Hormone + XRT	680	−	+	+	BS and CT
25	57	8	Orchiectomy + XRT	671	+	+	+	BS and CT

FDG, fluorine-18 fluorodeoxyglucose; PET, positron emission tomography; CT, computed tomography; PSA, prostate-specific antigen; BS, bone scan; PLND, pelvic lymph node dissection; Bx, biopsy; XRT, radiation therapy; +, positive; −, negative.